The LOPSAQ study: 48 week analysis of a boosted double protease inhibitor regimen containing lopinavir/ritonavir plus saquinavir without additional antiretroviral therapy

Journal of Antimicrobial Chemotherapy

Volumn 58, Issue 5, 2006, Pages 1024-1030

  Staszewski, Schlomo ^a   Babacan, Errol ^a   Stephan, Christoph ^a   Haberl, Annette ^a   Carlebach, Amina ^a   Gute, Peter ^b   Klauke, Stephan ^c   Hermschulte, Yvonne ^a   Stuermer, Martin ^a   Dauer, Brenda ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

^b Private HIV Practice Gute/Locher/Lutz   (Germany)

^c Internistisches Facharztzentrum   (Germany)

Author keywords

Boosted double PI; HIV drug resistance; Reverse transcriptase inhibitors; Toxicity

Indexed keywords

LOPINAVIR; PROTEINASE INHIBITOR; PYRIMIDINONE DERIVATIVE; RITONAVIR; SAQUINAVIR;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CD4+ T LYMPHOCYTE; CLINICAL TRIAL; COHORT ANALYSIS; DRUG INTERACTION; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGY; MALE; MIDDLE AGED; SALVAGE THERAPY; VIROLOGY; VIRUS LOAD;

ADULT; AGED; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; COHORT STUDIES; DRUG INTERACTIONS; FEMALE; HIV; HIV INFECTIONS; HIV PROTEASE INHIBITORS; HUMANS; MALE; MIDDLE AGED; PYRIMIDINONES; RITONAVIR; SALVAGE THERAPY; SAQUINAVIR; VIRAL LOAD;

EID: 34247147314     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkl375     Document Type: Article

References (36)

1. Nolan D, Hammond E, Martin A et al. Mitochondrial DNA depletion and morphologic changes in adipocytes associated with nucleoside reverse transcriptase inhibitor therapy. AIDS 2003; 17: 1329-38.
2. Shikuma CM, Shiramizu B. Mitochondrial toxicity associated with nucleoside reverse transcriptase inhibitor therapy. Curr Infect Dis Rep 2001; 3: 553-60.
3. Gallant JE, Staszewski S, Pozniak AL et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naïve patients: A 3-year randomized trial. JAMA 2004; 292: 191-201.
4. Gey DC, Lorenz T, Brust J et al. An NRTI-free regimen in HIV-patients with evidence of mitochondrial toxicity: 48 week results of pilot study. In: Programs and Abstracts of the Fifteenth International AIDS Conference, Bangkok, Thailand, 2004. Abstract TuPeB4512. International AIDS Society, Geneva, Switzerland.
5. Boyd MA, Siangphoe U, Duncombe CJ et al. Indinavir/ritonavir 800/ 100mg bid and efavirenz 600mg qd in patients with combination nucleoside failure: 96 week outcomes of HIV-NAT 009. In: Programs and Abstracts of the Fifteenth International AIDS Conference, Bangkok, Thailand, 2004 Abstract MoOrB1084. International AIDS Society, Geneva, Switzerland.
6. Duvivier C, Ghosn J, Assoumou L et al. Lower rate of virologic suppression in naïve patients initiating HAART with NRTI-sparing regimen compared to standard NRTI-containing regimen: Results from Hippocampe - ANRS 121 Trial. In: Program and Abstracts of the Tenth European AIDS Conference, Dublin, Ireland 2005. Abstract PS1. European AIDS Clinical Society (EACS), Paris, France.
7. Fischl M, Bassett R, Collier A et al. Randomized, controlled trial of lopinavir/ritonavir + efavirenz vs. efavirenz + 2 nucleoside reverse transcriptase inhibitors following a first suppressive 3- or 4-drug regimen in advanced HIV disease. In: Program and Abstracts of the Twelfth Conference on Retroviruses and Opportunistic Infections, Denver, CO, 2005; Abstract 162. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
8. Miller V, de Bethune MP, Kober A et al. Patterns of resistance and cross-resistance to human immunodeficiency virus type 1 reverse transcriptase inhibitors in patients treated with the nonnucleoside reverse transcriptase inhibitor loviride. Antimicrob Agents Chemother 1998; 42: 3123-9.
9. Yeni PG, Hammer SM, Hirsch MS et al. Treatment for adult HIV infection: 2004. Recommendations of the International AIDS Society-USA Panel. JAMA 2004; 292: 251-65.
10. Crommentuyn KM, Kappelhoff BS, Mulder JW et al. Pharmacokinetics of lopinavir in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005; 60: 378-89.
11. Winston A, Bloch M, Carr A et al. Atazanavir trough plasma concentration monitoring in a cohort of HIV-1-positive individuals receiving highly active antiretroviral therapy. J Antimicrob Chemother 2005; 56: 380-7.
12. Bergshoeff AS, Fraaij PL, Ndagijimana J et al. Increased dose of lopinavir/ritonavir compensates for efavirenz-induced drug-drug interaction in HIV-1-infected children. J Acquir Immune Defic Syndr 2005; 39: 63-8.
13. Kappelhoff BS, Huitema AD, Sankatsing SU et al. Population pharmacokinetics of indinavir alone and in combination with ritonavir in HIV-1-infected patients. Br J Clin Pharmacol 2005; 60: 276-86.
14. Boyd MA, Aarnoutse RE, Ruxrungtham K et al. Pharmacokinetics of indinavir/ritonavir (800/100 mg) in combination with efavirenz (600 mg) in HIV-1-infected subjects. J Acquir Immune Defic Syndr 2003; 34: 134-9.
15. Tashima KT, Bausserman L, Alt EN et al. Lipid changes in patients initiating efavirenz- and indinavir-based antiretroviral regimens. HIV Clin Trials 2003; 4: 29-36.
16. Moyle G, Baldwin C, Mandalia S et al. Changes in metabolic parameters and body shape after replacement of protease inhibitor with efavirenz in virologically controlled HIV-1-positive persons: Single-arm observational cohort. J Acquir Immune Defic Syndr 2001; 28: 399-401.
17. Garcia-Benayas T, Blanco F, de la Cruz JJ et al. Role of non-nucleosides in the development of HAART-related lipid disturbances. J Acquir Immune Defic Syndr 2001; 28: 496-8.
18. Hellinger J, Morris AB, Piscitelli S et al. Pilot study of saquinavir-SGC (Fortovase, saquinavir) 1000 mg twice daily and lopinavir/ ritonavir (Kaletra,LPV/r) in protease inhibitor-experienced HIV+ individuals: Dose escalation and combined normalized inhibitory quotient (cNIQ). In: Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002. Abstract 451-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
19. Ruiz L, Ribera E, Bonjochl A et al. Virological and immunological benefit of a salvage therapy that includes Kaletra plus Fortovase preceded or not by antiretroviral therapy interruption (TI) in advanced HIV-infected patients (6-month-follow-up). In: Program and Abstracts of the Ninth Conference on Retroviruses and Opportunistic Infections, Seattle, WA, 2002. Abstract 421-W. Foundation for Retrovirology and Human Health, Alexandria, VA, USA.
20. Smith GH, Boulassel MR, Klien M et al. Virologic and immunologic response to a boosted double-protease inhibitor-based therapy in highly pretreated HIV-1-infected patients. HIV Clin Trials 2005; 6: 63-72.
21. Zala C, Patterson P, Coll P et al. Virological response and safety at 48 weeks of double boosted protease inhibitors with Lopinavir/ ritonavir/r plus either saquinavir or amprenavir in heavily pretreated HIV infected patients. In: Programs and Abstracts of the Fifteenth International AIDS Conference, Barcelona, Spain, 2002. Abstract TuPeB4492. International AIDS Society, Geneva, Switzerland.
22. Stürmer M, Berger A, Doerr MW. Modifications and substitutions of the RNA extraction module in the ViroSeq™ HIV-1 Genotyping System Version 2: Effects on sensitivity and complexity of the assay. J Med Virol 2003; 71: 475-9.
23. Stephan C, von Hentig N, Kourbeti I et al. Saquinavir exposure is not impaired by the boosted double protease inhibitor combination of lopinavir/ritonavir. AIDS 2004; 18: 503-8.
24. Miller V, Mocroft A, Reiss P et al. Relations among CD4 lymphocyte count nadir, antiretroviral therapy, and HIV-1 disease progression: results from the EuroSIDA study. Ann Intern Med 1999; 130: 570-7.
25. Staszewski S, DeMasi R, Hill AM et al. HIV-1 RNA, CD4 cell count and the risk of progression to AIDS and death during treatment with HIV-1 reverse transcriptase inhibitors. AIDS 1998; 12: 1991-7.
26. Coombs RW, Welles SL, Hooper C et al. Association of plasma human immunodeficiency virus type 1 RNA level with risk of clinical progression in patients with advanced infection. AIDS Clinical Trials Group (ACTG) 116B/117 Study Team. ACTG Virology Committee Resistance and HIV-1 RNA Working Groups. J Infect Dis 1996; 174: 704-12.
27. O'Brien WA, Hartigan PM, Martin D et al. Changes in plasma HIV-1 RNA and CD4+ lymphocyte counts and the risk of progression to AIDS. Veterans Affairs Cooperative Study Group on AIDS. N Engl J Med 1996; 334: 426-31.
28. Mellors JW, Rinaldo CR Jr, Gupta P et al. Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 1996; 272: 1167-70.
29. Miller V, Phillips AN, Clotet B et al. Association of virus load, CD4 cell count, and treatment with clinical progression in human immunodeficiency virus-infected patients with very low CD4 cell counts. J Infect Dis 2002; 186: 189-97.
30. Egger M, May M, Chene G et al. Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: A collaborative analysis of prospective studies. Lancet 2002; 360: 119-29.
31. Cameron DW, Eron J, Farthing C et al. Comparative safety and anti-HIV activity of a dual protease inhibitor regimen (lopinavir/ ritonavir + saquinavir) versus a nucleoside-containing regimen. In: Programs and Abstracts of the Forty-fifth Interscience Conference on Antimicrobial Agents and Chemotherapy, Washington, DC, 2005, Abstract H-523. American Society for Microbiology, Washington, DC, USA.
32. Katlama C, Carvalho MTM, Cooper D et al. POWER-1: TMC114-C213 study. Week 24 primary analysis. In: Programs and Abstracts of the Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Abstract WeOaLB0.102. International AIDS Society, Geneva, Switzerland.
33. Lazzarin A, Mukwaya G, Clumeck N et al. Tipranavir/ritonavir (TPV/ r) demonstrates superior treatment response to lopinavir/ritonavir (LPV/ r), amprenavir/r (APV/r), and saquinavir/r (SQR/r) in PI-experienced patients from the RESIST-1 and RESIST-2 Trials. In: Programs and Abstracts of the Third International AIDS Society Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, Brazil, 2005. Abstract WePe6.3C07. International AIDS Society, Geneva, Switzerland.
34. Lalezari JP, Henry K, O'Hearn M et al. Enfuvirtide, an HIV-1 Fusion Inhibitor, for Drug-Resistant HIV Infection in North and South America. N Engl J Med 2003; 348: 2175-85.
35. Lazzarin A, Clotet B, Cooper D et al. Efficacy of enfuvirtide in patients infected with drug-resistant HIV-1 in Europe and Australia. N Engl J Med 2003; 348: 2186-95.
36. Thommes JA, Demasi R, Haubrich R. Improved virologic response in three-class experienced patients when an active boosted protease inhibitor is used with enfuvirtide (ENF). In: Programs and Abstracts of the Forty-third Annual Meeting Of Infectious Diseases Society of America, San Francisco, CA, 2005. Abstract 785. Infectious Diseases Society of America, Alexandria, VA, USA.